AAV-SLB102

AAV-SLB102 is an engineered adeno-associated virus capsid candidate being developed by Solid Biosciences for muscle-directed gene delivery, primarily in the context of Duchenne muscular dystrophy. It is not itself the therapeutic transgene product, but rather a vector capsid platform intended to improve delivery of gene therapy cargo to muscle tissue. Based on the provided context, AAV-SLB102 emerged from Solid Biosciences' capsid screening efforts and showed in vitro properties similar to related candidates in assays of cell binding, uptake, and microdystrophin expression in C2C12 cells, supporting its role as a research-stage gene delivery technology for neuromuscular disease applications.